Background: The use of sensitive molecular techniques to detect rare cells in a population is of increasing interest to the molecular pathologist, but detection limits often are poorly defined in any given molecular assay. We combined the approaches of real-time quantitative PCR with ARMS TM allele-specific amplification in a novel assay for detecting mutant K-ras sequences in clinical samples. Methods: ARMS reactions were used to detect seven commonly occurring mutations in the K-ras oncogene. These mutations produce amino acid changes in codon 12 (Gly to Ala, Arg, Asp, Cys, Ser, or Val) and codon 13 (Gly to Asp). A control reaction was used to measure the total amount of amplifiable K-ras sequence in a sample so that the ratio of mutant to wild-type sequence could be measured. Quantitative data were confirmed for a selection of samples by an independent cloning and sequencing method. The assay was used to analyze 82 lung tumor DNA samples. Results: The assay detected K-ras mutations in 44% of adenocarcinomas, which is equivalent to frequencies reported in the literature using ultrasensitive techniques. Forty-six percent of squamous carcinomas were also positive. The ratio of mutant sequence in the tumor DNA samples was 0.04 -100%. Conclusions: The assay is homogeneous, with addition of tumor DNA sample being the only step before results are generated. The quantitative nature of the assay can potentially be used to define the analytical sensitivity necessary for any specified diagnostic application of K-ras (or other) point mutation detection.
mutation analysis in lung disease include its use as a diagnostic marker of malignancy (of greater sensitivity than cytology alone) in sputum and bronchoalveolar lavage (BAL) 6 samples (17 ) and its use as a marker of prognosis in lung cancer patients (15, 18, 19 ) . The presence of K-ras mutations in lung tumors has been linked with shorter disease-free and overall survival (20 -23 ) . Some studies have also specified which codon 12 and 13 changes have prognostic value and which have less clinical relevance (24, 25 ) . Improved stratification of lung tumors using molecular markers such as K-ras may lead to the identification of a patient subgroup who require a more aggressive therapy.
Techniques for the detection of K-ras mutations in clinical samples have been reviewed (26 ) . Because the detection limits of currently used methods vary, different assays used for the same clinical application lead to different results. It is therefore vital for any novel technique to be fully validated so that the sensitivity and specificity of mutation detection in the relevant clinical sample can be determined. The limit of detection then needs to be taken into account when comparing data obtained by use of different molecular assays to answer the same clinical question (27 ) . We investigated two approaches to K-ras mutation detection in samples from lung cancer patients. Both methods used allele-specific amplification (ARMS TM ) for mutant sequence discrimination. The first method, the Elucigene K-RAS7 method (AstraZeneca Diagnostics, Abingdon, UK), is similar to a previously reported assay (28 ) . The second, a real-time ARMS assay, provides quantitative data for samples positive for K-ras mutations. The real-time quantitative approach, with its sensitive detection and mutant sequence quantification, allows the determination of the true detection limit in any clinical application.
Materials and Methods dna extraction
Primary lung tumor samples were obtained from patients undergoing surgery in the Cardiothoracic Centre of Broadgreen Hospital, Liverpool. DNA was extracted from formalin-fixed, paraffin-embedded or frozen tissue sections using a solution of 400 mmol/L Tris-HCl, 150 mmol/L NaCl, 60 mmol/L EDTA, 10 g/L sodium dodecyl sulfate, and 0.2 g/L proteinase K (Sigma-Aldrich) for 2 h at 60°C. Additional proteinase K was added to a final concentration of 0.3 g/L, and incubation was continued for 16 h at 40°C. Samples were deproteinized by the addition of NaClO 4 to 1.1 mol/L, followed by chloroform extraction. DNA was precipitated with isopropanol at Ϫ20°C, washed with 700 mL/L ethanol, and redissolved in 20 -50 L of distilled water.
allele-specific amplification
Two systems that detect the seven most commonly reported K-ras mutations in codons 12 and 13 of exon 1 were used in this study. The prototype of a commercially available method (Elucigene K-RAS7) has been described previously (29 ) .
The Elucigene K-RAS7 method was used in exact compliance with the manufacturer's instructions. Briefly, 5 L of each DNA sample was added to each reaction mixture and thermocycled in a 9600 machine (PE Applied Biosystems). AmpliTaq Gold DNA polymerase activation was carried out at 94°C for 20 min, followed by 36 cycles of 94°C for 45 s (denaturation), 63°C for 45 s (annealing); and 72°C for 45 s (extension), with a final extension step of 72°C for 10 min. Amplification products were analyzed by gel electrophoresis in accordance with the manufacturer's recommendations.
real-time arms K-ras mutation analysis
The second system combined the approach described above with real-time fluorescent detection of amplification products, thus introducing quantification into the basic ARMS format ( Fig. 1 ). Amplification products were detected by molecular beacons (30 ) . Each reaction contained 50 mol/L ARMS and common primers, 100 mol/L beacon, and 60 nmol/L ROX internal reference (PE Applied Biosystems) together with the standard reaction components described previously (29 ) . 2Ј-O-Methyl RNA beacons complementary to the sense and antisense strands of K-ras exon 1 were designed: 5Ј-FAM-C G C G G U C C C U U G A C G A U A C A G C U A A U U -CAGAACGCG-MR-3Ј and 5Ј-FAM-CGCGGUGCU-GAAAAUGACUGAAUAUAAACUUGUGGACGCG-MR-3Ј, respectively. Both probes were labeled with a 5Ј 6-carboxyfluorescein (FAM) fluorophore and a 3Ј methyl red (MR) monomer, which acted as a nonfluorogenic (dark) quencher (Oswel DNA Service). 2Ј-O-methyl RNA and not DNA was used here to avoid fluorescent signal generation from the 5Ј-3Ј exonuclease activity of Taq polymerase. The cycling conditions were as follows: 94°C for 20 min to activate the AmpliTaq Gold (PE Applied Biosystems), followed by 50 cycles of a 94°C denaturation step and a 60°C combined annealing and extension step. An additional reaction, designed to amplify all K-ras exon 1 sequences, was carried out under the same conditions as for the mutant-specific reactions (Fig. 2) . When amplification occurred, relative fluorescence increased exponentially in relation to cycle number, and the point at which it passed a fixed threshold above baseline was defined as the threshold cycle number, or C t (in accordance with PE Applied Biosystems).
With real-time ARMS K-ras mutation detection as described above, a reference data set was generated to establish background signals in the absence of mutations, using wild-type genomic DNA extracted from the periph-eral blood of 12 healthy volunteers. This consisted of more than 2000 individual amplifications using DNA of a predetermined concentration. DNA was extracted using a DNA extraction method (Qiagen). DNA was quantified with care (A 260 readings were taken from multiple dilutions of each stock DNA to ensure maximum accuracy of quantification). Initial template concentrations of 1 ϫ 10 3 , 1 ϫ 10 4 , and 1 ϫ 10 5 diploid genome-equivalents (defined as 6 -600 ng) of human DNA were selected as the dynamic range over which control data would be generated.
Results of the eight real-time ARMS reactions (C t values)
were analyzed by plotting K-ras mutant ARMS reaction C t against control C t .
Twelve peripheral blood DNA samples were analyzed for each ARMS reaction in batches of eight replicates at three concentrations, by three independent operators. This gave a total of 288 results for each ARMS test and 2016 reactions in total. Inauthentic priming of mutantspecific ARMS primers occurs at extremely low efficiency on wild-type DNA. This gives rise to a yield of inauthentic (non-mutant-derived) product (Y i ) during a 50-cycle amplification. Statistical analysis of product appearance (the C t value at which amplification products are first detected when fluorescent signal increases above the threshold value) attributable to rare mispriming on wild-type DNA alone, from the 2016 separate reactions, was therefore performed. One-sided prediction intervals were calculated on linear regression analyses of the Y i data for each ARMS reaction, and 98% confidence limits were then set for subsequent analysis of samples of unknown mutant status. C t values from clinical samples of unknown K-ras mutant status containing the wild-type K-ras exon 1 sequence have only a 1% probability of falling below the 98% confidence limit. (A), when an ARMS primer binds to mutant target DNA, extension and amplification occurs. On the corresponding wild-type target, which may be present in great excess, the 3Ј nucleotide is not matched, and amplification can only occur at extremely low efficiency. Amplification products can be detected by sequence-specific probes that have been fluorescently labeled. In our assay, molecular beacons (30 ) have been used to detect amplification products. (B), 11 DNA samples are usually added to all eight ARMS reactions and a control reaction (for total DNA amount) in a 96-tube format. The final column of tubes has no DNA added to control for contamination. The reactions are thermocycled in the ABI 7700 (PE Applied Biosystems), which measures and records fluorescent signal during amplification.
Mutant-only reactions were set up using cloned DNA sequences corresponding to each of the seven most prevalent K-ras mutations, as described previously (29 ) . As a control, the wild-type cloned K-ras sequence was amplified in the real-time assay to ensure that there were no significant differences in the background signals generated when either genomic DNA or amplicon was used as template. Mutant and wild-type cloned DNA templates were amplified over a concentration range similar to that described above for the genomic template. All of the cloned and amplified K-ras sequences were verified by standard sequencing methodology (data not shown).
DNA derived from lung tumor samples of unknown K-ras mutant status was analyzed in relation to the data described above. A 5-L aliquot of each sample was added to the seven ARMS reactions and a control reaction. The reactions were thermocycled and analyzed in an ABI 7700 as described above. The ratio of mutant to wild-type K-ras exon 1 in the mutant-positive tumor samples was calculated from the data obtained using the cloned mutant K-ras sequence. This was done by interpolation from the equation of the regression analysis of results obtained using 100% mutant K-ras sequence. For example, in the codon 12 Gly-to-Arg reaction, the equation of the 100% mutant regression line was: y ϭ 0.9955x Ϫ 0.5808, where y is the ARMS C t , and x is the control C t . Therefore, a sample with a control C t of 32 cycles would have an ARMS C t of 31.3 cycles if it contained 100% mutant (Gly-to-Arg) K-ras alone. However, if the actual ARMS C t value was 32.3 cycles or 33.3 cycles, then the sample contained 50% or 25% mutant DNA, respectively. This calculation assumes a doubling in amplification product amount after each cycle (31 ) . To control for this mathematical calculation, samples with established mutant-to-wild-type ratios, from cloning and sequencing experiments (29 ) , were analyzed empirically, and the ratio of mutant to wild-type sequence was compared.
mutation detection by pcr-allele-specific oligonucleotide hybridization
Lung tumor DNA samples, analyzed in this study by the real-time assay, were independently analyzed by PCRallele-specific oligonucleotide (ASO) hybridization. Briefly, samples were amplified in two rounds of PCR, each consisting of 35 cycles of 94°C for 1 min, 60°C for 1 min, and 72°C for 1 min. PCR products were purified using the Wizard reagent set (Promega), and their concentrations were estimated by agarose gel electrophoresis using molecular weight markers (Life Technologies). Approximately 40 ng of PCR product was transferred to Hybond Nϩ membrane (Amersham Pharmacia Biotech). Labeled ASO probe (40 ng) was hybridized to the membrane at 40°C, filters were washed using 3 mol/L tetramethylammonium chloride (Sigma) at 56°C, and probe was detected as described in the ECL method (Amersham Pharmacia Biotech). The sensitivity of the ASO approach was established using carefully prepared mixtures of mutant and wild-type genomic DNA (50%, 20%, 10%, 5%, and 1% mutant) as described previously (29 ) . A selection of lung tumor DNA samples, positive for a mutation by real-time analysis, were analyzed by ASO hybridization. Tumor DNA samples that were found to contain only wild-type K-ras by real-time analysis were analyzed by ASO as a control.
Results
The presence of K-ras mutations, as detected by ARMS (Table 4) , was confirmed by two alternative methods. In the first method, an ASO-based assay was used to verify the results for a selection of mutation-positive lung tumor samples. Fig. 3 shows the ASO hybridization results for the codon 12 GGT-to-CGT (Gly-to-Arg) change. The signals for 50%, 20%, 10%, 5%, and 1% mutant controls (mutation-positive cell line/wild-type DNA admixtures) were higher than signals observed for controls representing the six other K-ras mutations or tumor samples known to contain mutations other than Gly-to-Arg. Sample 42, however, was positive for the Gly-to-Arg mutation by real-time analysis and had a signal above background by ASO. Signals from lung tumor samples containing high concentrations of codon 12 Gly-to-Cys mutant DNA were higher than the background wild-type signal ( Fig. 3 ). For example, sample 38 contained 100% mutant Cys DNA by real-time analysis, and this cross-reacted with the ASO probe for the codon 12 Gly-to-Arg mutation. The probe, intended to be specific for Arg, contains a guanosine at the first position of codon 12, complementary to the cytosine in mutant (Gly-to-Arg) K-ras exon 1. This interacts very weakly with the guanosine at the same position The mutant ARMS primer discriminates between mutant and wild-type (Normal) genomic copies of K-ras exon 1 in any given clinical DNA sample. The control reaction amplifies all K-ras exon 1 sequences regardless of mutation status. The relationship between the appearance of amplification products from the ARMS and control reactions is a quantitative measure of the amounts of mutant and wild-type sequences in the clinical sample.
in wild-type DNA. However, the codon 12 Gly-to-Cys mutation, resulting from a guanosine-to-thymidine change at this position, means that the ASO probe binds with a higher affinity and so gives a higher signal than other codons (G-T mismatches are weakly destabilizing compared with G-G mismatches) (32 ) .
A second approach was used to confirm the mutation status derived from the ARMS assays. Colorectal tumor DNA samples, in which K-ras mutant sequences were quantified previously by cloning and sequencing (29 ) , were tested in the new ARMS assay. These samples were analyzed using the real-time assay, and mutant/wildtype quantities were compared. The results of these experiments are summarized in Table 1 . The reported frequencies obtained by the two approaches were largely in agreement, and discrepancies may have been attributable to sampling issues because different aliquots of the tumor DNA samples were analyzed at two different geographic sites with a long time interval between measurements (3 years). These two approaches confirmed both the qualitative and quantitative aspects of the realtime ARMS assay, within the sensitivity range of the ASO procedure (Ն5% mutant target).
An example of the Elucigene K-RAS7 assay results are shown in Fig. 4 . Tumor DNA was extracted from both paraffin-embedded and frozen tissue samples. The paraffin-embedded tissue samples in general showed either partial or complete loss of the upper control product (360 bp). This is characteristic of amplified DNA obtained from this sample source in which genomic DNA is generally degraded. The lower control product (111 bp) usually is present even when the upper control is missing. The ARMS products were 158 -190 bp in length, and were therefore largely unaffected by the DNA degradation observed for paraffin-embedded samples. However, in samples where the upper control product was missing and the lower control was present (although absence of an ARMS product is probably attributable to the fact that the sample is wild type), DNA fragmentation may have The autoradiograph shows results from the codon 12 Gly-to-Arg-specific ASO hybridization. Samples were analyzed blind by an independent operator. Cell line DNA representing each of seven K-ras mutations was mixed in decreasing amounts (50%, 20%, 10%, 5%, and 1%) with wild-type genomic DNA. PCR products in samples 1, 8, 15, 22 , and 29 correspond to 50%, 20%, 10%, 5%, and 1% codon 12 Gly-to-Ser mutant DNA, respectively. The same positive control amounts were analyzed for each K-ras mutation: samples 2, 9, 16, 23, and 30, codon 12 Gly-to-Val; samples 3, 10, 17, 24, and 31, codon 12 Gly-to-Asp; samples 4, 11, 18, 25, and 32, codon 12 Gly-to-Cys; samples 5, 12, 19, 26, and 33, codon 13 Gly-to-Asp; samples 6, 13, 20, 27, and 34, codon 12 Gly-to-Ala; samples 7, 14, 21, 28, and 35, codon 12 Gly-to-Arg. Samples 36 and 37 are products from wild-type control DNA samples extracted from peripheral blood. Six lung tumor samples were included that were positive for codon 12 Gly-to-Cys (sample 38), codon 12 Gly-to-Val (sample 39), codon 12 Gly-to-Ser (sample 40), codon 12 Gly-to-Ala (sample 41), codon 12 Gly-to-Arg (sample 42), and codon 12 Gly-to-Asp (sample 43). Two PCR-negative controls (samples 44 and 45) and one water control (sample 46) were also used. a Amount of mutant K-ras exon 1 calculated using the real-time assay. b Amount of mutant K-ras exon 1 calculated using the cloning and confirmatory sequencing method described by Fox et al. (29 ) . c Number of clones analyzed to obtain the quantitative data in Fox et al. (29 ) . occurred, i.e., fragmentation of target mutant genomic DNA above 111 bp (lower control product size) in length. These events were recorded as wild type in the results summarized in Table 2 . Tumor samples 45, 75, 84, and 120 were positive for codon 12 GGT-to-GAT (Gly-to-Val) mutations, as indicated by the presence of ARMS products on the gel (Fig.  4) . DNA concentrations after extraction from the lung tissue were not standardized before amplification, and this most likely accounted for the visible differences in overall product yields among the samples. One advantage of the real-time assay is that initial DNA concentrations do not require standardization.
K-ras mutations were detected in 15% (9 of 62) lung tumor DNA samples by Elucigene KRAS-7 ARMS analysis (Table 2. ). Nineteen percent of adenocarcinomas and 10% of squamous cell carcinomas were found to have mutations. No K-ras mutations were detected for the other lung tumors analyzed. The frequencies of the mutant sequences in K-ras-positive lung tumor samples were calculated using real-time analysis, by interpolation from the equation of the regression analysis for 100% mutant DNA for each ARMS reaction, and were expressed as percentage of total K-ras exon 1 in the samples ( Table 3 ). All mutations detected by the Elucigene K-RAS7 method were also detected by real-time analysis. Twenty additional squamous cell carcinomas were analyzed by the real-time assay to further characterize K-ras mutations occurring in this tumor type. The results of the real-time analyses are summarized in Table 4 . The ratios of mutant to wild-type sequences in the positive samples were expressed as percentages of the total number of K-ras exon 1 sequences ( Table 5 ).
The nature of ARMS mispriming on non-mutant DNA is determined by the 3Ј nucleotide species that mispairs with the wild-type nucleotide in the target sequence. These mismatches are not absolute and produce rare priming events, occurring at extremely low efficiencies, that depend on the strength of the mismatched base pair interaction (32 ) . These rare mispriming events were controlled for in our assay, thus allowing the reliable analysis of clinical samples of unknown K-ras status. The strength of the mismatched base pair interaction is reflected in the Y i data for each test (see Fig. 5 ). For example, in the codon 12 Gly-to-Ala test (Fig. 5B) , the ARMS primer specific for the GGT-to-GCT change has a 3Ј terminal guanosine that is strongly destabilized from the guanosine at position 2 in codon 12 in wild-type K-ras. This means that Y i resulting from inauthentic priming events in this assay is rarely seen. In the codon 12 Gly-to-Asp test (Fig. 5A) , the ARMS primer has a 3Ј terminal thymidine mismatched with the guanosine in wild-type K-ras exon 1. This interaction is less destabilizing, and so Y i appears earlier in the amplification process.
Negligible variations in Y i data were observed between operators or between DNA samples of equivalent DNA concentration (results not shown). Fig. 5 shows the realtime data for all lung tumor samples in all seven ARMS tests. As described in Materials and Methods, tumor samples were analyzed in relation to Y i data to determine mutational status. There was a 1% chance of a sample appearing below the lower limit of the 98% confidence interval if it contained wild-type sequence alone, and if such a case was observed, it was considered positive for the mutation interrogated by that specific ARMS primer. Duplicate analysis of each sample markedly reduced the chance of a sample appearing as mutation-positive twice when it contained wild-type sequence alone. The quantity of mutant sequence in these samples was calculated by interpolation using the 100% mutant data (not shown). Fifty cycles is the endpoint of the assay, and samples were ascribed a C t of 50 cycles if they had not yielded a detectable ARMS product by this point in the amplification process. The majority of tumor samples were negative for K-ras mutations in each test. This provided the opportunity to observe the nature of mispriming events for individual ARMS primers on the wild-type K-ras exon 1 sequence. At high concentrations of starting genomic target DNA (Ͼ1 ϫ 10 4 copies), mispriming events did occur, and Y i appeared relatively early and with limited variability. At lower starting template concentrations, however, mispriming events were rarer and amplification varied stochastically, with detection of Y i dramatically reduced to the extent that samples often gave no detectable product up to 50 cycles. Addition experiments conducted with low ratios of mutant to wild-type DNA added to a K-ras mutant-negative tumor sample showed that this type of sample still yielded ARMS products below the background cutoff for wild-type DNA if mutant sequence was present (data not shown).
Discussion
In the real-time assay, 44% (16 of 36) of adenocarcinomas were positive for K-ras mutations, whereas 19% (7 of 36)
were positive in the Elucigene method. The frequency of positives obtained using the real-time assay was higher than some published data, which reflects differences in assay sensitivity. Mutation frequencies of 29% (17 of 58) (24 ) , 26% (47 of 184) (25 ) , and 28% (19 of 69) (15 ) have been reported for ASO-based studies. Frequencies of 38% (6 of 16) (22 ) and 11% (10 of 88) (21 ) have been reported for a single-strand conformation polymorphism study, with confirmatory sequencing of samples that were positive by single-strand conformation polymorphism analysis. A restriction fragment length polymorphism assay (23 ) , with a sensitivity of 10%, found 8% of adenocarcinomas positive for K-ras mutations. Using ultrasensitive assays that use restriction enzymes to cut wild-type amplicon and thus enrich for mutant K-ras amplicon during additional rounds of amplification, investigators found 46% (13 of 28) of adenocarcinomas positive for K-ras mutations (33 ) . This is similar to the frequency observed in the real-time ARMS assay in this study (44%). The real-time assay is a more convenient and highly reproducible method by comparison. Any laboratory routinely using sensitive assays involving multiple rounds of amplification and manipulation of PCR products may be prone to contamination problems even with the strictest control measures in place. The real-time assay has the advantages of being homogeneous and requiring no manipulation of amplification products. In addition, data were obtained over a dynamic range of DNA concentrations to facilitate direct analysis of DNA routinely extracted from clinical samples without the need to standardize DNA input amount.
There are two major reasons for the increased sensitivity of the real-time assay over the Elucigene method and other assay systems. The assay was designed to identify mutation-positive samples as "not wild type" by comparison to a data set obtained using wild-type DNA alone. This maximizes sensitivity compared with alternative methods that specify a cutoff at which the "signal" is considered positive in relation to a positive control containing a low mutant fraction. In addition, the behavior of the ARMS primers on wild-type DNA was established over a dynamic concentration range (100-fold) in a 50- GCT  CGT  GAT  TGT  AGT  GTT   Adenocarcinoma  0  1  2  1  0  3  0  7  19% (7/36 cycle amplification. This range was chosen by reference to DNA yields routinely obtained from various clinical samples entering our laboratory (tissue and cell suspensions in body fluids). Therefore, unknown clinical samples containing different DNA amounts in the fixed assay volume could all be analyzed in the same 50-cycle amplification. Measurement and standardization of the DNA concentration before any molecular assay can be unrealistic in the clinical setting when overall yields are low and the sample is limited. If an assay involves PCR with an early fixed endpoint (to maintain specificity), then unknown samples with low DNA concentrations and K-ras mutations will be reported as false negatives.
It is worth pointing out that a high percentage of squamous cancers were positive for K-ras mutations in this study. Mutations in the K-ras oncogene are not restricted to adenocarcinomas, and other investigators have demonstrated this (24, 34 ) or referred to it (28 ) . There may be several reasons for differences in perception concerning the occurrence of K-ras mutations and whether they are restricted to the adenocarcinoma tumor type. These may include differences in the molecular assays used and heterogeneity of the tumor tissue. Multiple sections from a tumor sample may indicate either adenocarcinoma or squamous histological types, and this gives rise to the possibility that a histological definition of tumor type may not reflect the true nature of the cell population analyzed for K-ras mutations. There were no differences in the amounts of K-ras mutant sequence between the adenocarcinoma and squamous carcinoma types in this study.
The clinical significance of the quantity of K-ras mutation in a positive clinical sample is yet to be established. One study has separated K-ras results into low-fraction and high-fraction positives. The authors reported an increased stage of disease and decreased survival linked to the high-fraction positives, although statistical significance was not reached with the limited number of samples investigated (34 ) . Mutation of the K-ras oncogene is considered an early event in lung cancer development (35 ) , although not necessarily the first (36 ) , and measurement of the mutation fraction may simply reflect disease stage. Larger studies using quantitative assays may establish the clinical relevance of molecular markers in relation to treatment or survival endpoints. Quantitative data may also be important when looking for malignant cells distant to the site of a tumor, such as in the screening or early diagnosis setting, where less-invasive clinical procedures are used. Quantitative data could be used in establishing the required assay sensitivity for a particular clinical application. For example, in lung cancer this would involve the analysis of sputum and BAL samples to potentially detect clinically occult tumors. Matched K-ras mutations have been demonstrated in adenocarcinomas of the lung and corresponding sputum (37 ) and BAL (38 ) samples in lung cancer patients. To date, we have used our assay on 108 bronchial lavage samples (58 from patients with a confirmed malignancy and 50 from nonmalignant cases). In five mutation-positive BAL samples, cytology reported no malignant cells present despite malignancy being confirmed (data not shown). Three of eight BALs from confirmed adenocarcinomas were positive in the assay. One of 50 non-malignant cases was positive, with the patient reported as having heart disease.
The real-time assay used here offers a unique opportunity to assess the clinical significance of K-ras mutations in lung and other cancers. The sensitive nature of the GCT  CGT  GAT  TGT  AGT  GTT   Adenocarcinoma  3  3 b  3 b  3  0  6 b  0  16  44% (16/36 assay provides the opportunity to screen large numbers of clinical samples for malignant cells in the early detection setting. The utility of K-ras mutation detection in BAL samples as a precursor to lung cancer diagnosis has been demonstrated previously (37 ) . At present, we are using this method to investigate the utility of K-ras mutation detection for pancreatic and colorectal disease management. The assay has been designed to facilitate highthroughput sample analysis after routine nucleic acid extraction procedures for a range of clinical materials.
